Dr. Reddys Laboratories Ltd

Hyderabad, India

Dr. Reddys Laboratories Ltd

Hyderabad, India
SEARCH FILTERS
Time filter
Source Type

The invention relates to a cell culture process for decreasing the galactosylated content and/or increasing the G0F content of a glycoprotein. The process involves subjecting recombinant cells expressing the said glycoprotein to a temperature and pH shift and supplementing cell culture with glutamine.


Patent
DR. REDDYS LABORATORIES Ltd | Date: 2017-04-13

The present application relates to crystalline and amorphous Vilazodone hydrochloride. The present application further relates to amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of form I of vilazodone free base.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2017-03-15

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.


Patent
DR. REDDYS LABORATORIES Ltd | Date: 2017-01-10

The present invention relates to stable liquid pharmaceutical formulations of cyclophosphamide comprising cyclophosphamide and at least one pharmaceutically acceptable excipient wherein moisture content of the liquid formulation is less than about 2.0% by weight. The invention further relates to stable liquid formulations of cyclophosphamide prepared by a process comprising a step of reducing the moisture content from cyclophosphamide or liquid compositions of cyclophosphamide or both. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders.


Patent
Dr. Reddys Laboratories Ltd., Sasmal, Ahmed, Tehim and Paradkar | Date: 2017-04-26

The present application relates to a series of substituted imidazo[l,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2017-06-14

A process for preparing Nilotinib hydrochloride Form R5 and Form R6 comprises: step a) providing a solution of Nilotinib free base in acetic acid and optionally an organic solvent, step b) adding hydrochloric acid taken in an organic solvent to the solution of step a), then separating Nilotinib hydrochloride Form R5 (step c), and finally drying at about 100 C to 150 C to obtain Nilotinib hydrochloride Form R6.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2016-01-29

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.


Patent
DR. REDDYS LABORATORIES Ltd | Date: 2017-02-16

The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T_(max )value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T_(max )substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2017-05-10

The present application relates to the solid state forms of Eliglustat hemitartrate and the processes for the preparation thereof. The application further provides solid dispersion of Eliglustat hemitartrate having Eliglustat hemitartrate in amorphous form.


Patent
Dr. Reddys Laboratories Ltd. | Date: 2017-05-10

Aspects of the present invention provide stable liquid ready-to-use injectable formulation of bortezomib or pharmaceutically acceptable salts thereof. Another aspect of the present invention provides processes for preparation of such stable liquid ready- to-use injectable formulation of bortezomib and methods of using such formulations for treating various types of cancers in mammals.

Loading Dr. Reddys Laboratories Ltd collaborators
Loading Dr. Reddys Laboratories Ltd collaborators